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Abstract
Background High-intensity focused ultrasound (HIFU)
ablation is a relatively new, noninvasive way of ablation
for treating hepatocellular carcinoma (HCC). Emerging
evidence has shown that it is effective for the treatment of
HCC, even in patients with poor liver function. There is
currently no data on the safety limit of HIFU ablation in
patients with cirrhosis. However, this information is vital
for the selection of appropriate patients for the procedure.
We analyzed HCC patients who had undergone HIFU
ablation and determined the lower limit of liver function
and other patient factors with which HCC patients can
tolerate this treatment modality.
Methods Preoperative variables of 100 patients who
underwent HIFU ablation for HCC were analyzed to
identify the risk factors in HIFU intolerance in terms of
stress-induced complications. Factors that may contribute
to postablation complications were compared.
Results Thirteen (13 %) patients developed a total of 18
complications. Morbidity was mainly due to skin and
subcutaneous tissue injuries (n = 9). Five patients had
first-degree skin burn, one had second-degree skin burn,
and three had third-degree skin burn. Four complications
were grade 3a in the Clavien classification and 14 were
below this grade. Univariate analysis showed that age
(p = 0.022) was the only independent factor in HIFU
intolerance.
Conclusions HIFU ablation is generally well tolerated in
HCC patients with cirrhosis. It is safe for Child-Pugh A and
B patients and selected Child-Pugh C patients. With this
new modality, HCC patients who were deemed unsal-
vageable by other surgical means in the past because of
simultaneous Child-Pugh B or C disease now have a new
hope.
Introduction
Advances in surgical techniques have improved the sur-
vival of patients with hepatocellular carcinoma (HCC)
considerably during the past years. However, as few as
25 % of HCC patients are amenable to surgical resection
on presentation. The low resectability rate is mainly due to
marginal liver function reserve, a condition secondary to
chronic liver disease, such as cirrhosis [1]. Locoregional
ablative therapies offer good alternatives to resection for
HCC patients who are awaiting liver transplantation, a
treatment modality that benefits far fewer patients than it
should because of the severe shortage of liver grafts [2, 3].
Among various methods of ablation for HCC, radio-
frequency ablation (RFA) is relatively popular because it is
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effective, simple, and repeatable [4, 5]. Nonetheless, it is
an invasive procedure and, according to a review of reports
involving 3,670 patients, it had an overall complication rate
of 8.9 % [6, 7]. RFA involves direct tumor puncturing,
which may precipitate direct tumor seeding, particularly
when the lesion is close to a major hepatic vessel. For some
patients, such as those with gross ascites, RFA is not viable
at all. High-intensity focused ultrasound (HIFU) ablation is
a newly emerged alternative that seems promising for the
management of HCC, even for patients with advanced
cirrhosis and gross ascites [8].
HIFU modality
HIFU treatment is a totally extracorporeal noninvasive
ablation mode using focused ultrasound energy that is
capable of causing coagulative necrosis of the targeted
HCC via intact skin without the need of surgical incision
[9, 10]. It utilizes a unique frequency of ultrasound wave of
0.8–3.5 MHz, which can be focused at a distance from the
therapeutic transducer. The accumulated energy at the
focused region induces necrosis of the target lesion by
elevating the tissue temperature to greater than 60 C.
Temperature outside the focus point remains static as
particle oscillation remains minimal. Because ultrasound
energy travels much better in water than in air, the presence
of ascites in HCC patients actually facilitates energy
propagation to the targeted HCC. Passage of energy with-
out the puncture of a physical instrument and its superior
performance in patients with ascites give HIFU treatment
superiority over other treatment modalities for HCC.
Initial results of HIFU ablation for the management of
HCC were promising with a complete ablation rate of
28.5–68 % for single treatment [8, 11, 12]. Once consid-
ered a ‘‘chinoiserie,’’ HIFU ablation is gaining popularity
in other parts of the world [13–15]. But unlike partial
hepatectomy or RFA for HCC patients with cirrhosis, there
are limited data on the safety limits for HIFU ablation, yet
this kind of information is vital for the selection of
appropriate patients for the procedure. To our knowledge,
no study has evaluated HCC patients’ tolerance of HIFU
ablation. In this study, we analyzed the results of HIFU
ablation in HCC patients and determined the lower limit of
liver function with which HCC patients can tolerate this
treatment modality.
Patients and methods
From October 2008 to June 2010, 100 patients received
HIFU ablation for HCC at our center. They all underwent a
complete set of liver function tests. Diagnosis of HCC was
based on two typical imaging findings, together with
cytology and histopathology examination results if previ-
ous surgery had been performed. Contrast magnetic reso-
nance imaging scans were interpreted by consultant
radiologists. A lesion was considered HCC-positive if
it demonstrated the typical vascular pattern of HCC
(i.e., hypervascular in the arterial phase with washout in the
portal venous phase) and an increased signal of lesion in
T2W image. A serum alpha-fetoprotein level [400 ng/ml
was considered significantly diagnostic of HCC.
Upon diagnosis of HCC, patients were evaluated for
treatment according to the following general principles.
Surgical resection is offered to patients with suitable
tumors and liver function that can tolerate it as decided by
indocyanine green retention test and liver volumetry. Open
RFA is offered for tumors \5 cm if surgical resection is
deemed risky. Liver transplantation is considered for
patients with poor liver function and tumors within the
UCSF criteria. Percutaneous RFA by interventional radi-
ologist is offered to patients who have unresectable HCC
due to poor liver function and patients who refuse open
RFA and surgical resection. HIFU ablation is offered to
patients not suitable for percutaneous RFA but with satis-
factory general condition as assessed by anesthesiologist.
Transarterial chemoembolization (TACE) is used to treat
nonablatable tumors. Patients with any of the following
problems are precluded from HIFU therapy: tumor inva-
sion of a major hepatic blood vessel; extrahepatic metas-
tasis of disease; unsuitability for general anesthesia;
receiving medical treatment that may cause skin compli-
cation (e.g., targeted therapy).
HIFU ablation is an accepted and standard practice of
treatment for unresectable HCC at our center [16]. All
HIFU treatments in the present series were performed by
our center’s HIFU team consisting of experienced surgeons
in hepatobiliary and pancreatic surgery and experienced
radiologists. The first author attended every HIFU treat-
ment since 2007, involving 80 % of all cases performed.
Our center has been employing the JC HIFU system
(Chongqing Haifu Technology, Chongqing, China) for
HIFU treatment. The JC HIFU system comprises a real-
time diagnostic imaging unit, a therapeutic unit, a degassed
water circulation unit, and a computer system. The real-
time diagnostic imaging unit provides direct visualization
of the tumor. The therapeutic unit consists of an ultrasound
energy transducer which focuses the ultrasound energy at a
12-cm focal point. The degassed water circulation unit
provides a medium for ultrasound transmission outside the
body. The computer system controls these three units. The
actual operative setting is shown in Fig. 1.
All patients were subjected to general anesthesia to aid
their comfort, because the whole procedure could last for
3 h and the patients had to lie still and were subjected to
long periods of breath-holding. In addition, general
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anesthesia allowed manipulation of tumor location by
inducing the Valsalva maneuver during the procedure by
the anesthesiologist. Artificial right pleural effusion before
treatment was required for the ablation of lesions adjacent
to the ribs or close to the dome of the liver to displace the
lung parenchyma from the pathway of the ultrasound beam
and to provide an acoustic window for the treatment. After
anesthetic induction, the patient was placed in a left-lateral
position and pleural puncture was performed at the right
fourth intercostal space along the midaxillary line, using an
18-gauge Tuohy needle with a passive loss of resistance to
a falling column of fluid. Approximately 800 ml of warm
normal saline was required. Ventilation was suspended in
the expiratory phase with an open adjustable pressure limit
valve when the needle was introduced to the pleural cavity.
HIFU treatment was performed under real-time ultrasound
image guidance. Target lesions were localized by a
3.6-MHz diagnostic ultrasound probe (Philips) incorpo-
rated at the center of the transducer. Diagnostic and ther-
apeutic ultrasound waves were emitted synchronously in
the same direction. Detailed planning was performed
according to the tumor size and location as shown on the
computer monitoring module, which was synchronized
with the real-time diagnostic imaging probe. Parallel slices
of the target tumor with 5-mm separations were planned
and then ablated slice by slice with focused ultrasound
energy produced by the transducer operating at 0.8 MHz.
Grey-scale changes of the ablated sites were observed
during the ablation procedure, indicating the temperature
change inside the target lesion [17].
Postoperative blood tests for complete blood picture,
prothrombin time and liver and kidney functions were
performed routinely on days 1, 3, 7, and 14, or according to
specific clinical situations. All patients were closely
observed for any development of complications and had
routine blood tests according to the protocol. Contrast
computed tomography or magnetic resonance imaging was
performed 1 month after treatment. The results were
interpreted by a consultant radiologist together with
another radiologist. Complete ablation was defined as full
coverage of the lesion by HIFU scar at the first imaging.
Repeated HIFU was performed for incomplete ablation.
Reasons for readmission were recorded. Cases in which
complications developed after HIFU treatment were ana-
lyzed to determine the risk factors for intolerance of the
treatment. Intolerance was defined as one or more com-
plications occurring secondary to the procedure.
For this study, intractable ascites was defined as a
collection of abdominal fluid resistant to diuretics or
a collection of abdominal fluid requiring paracentesis.
‘‘Massive’’ pleural effusion was that which required drain-
age for dyspnea or desaturation. Encephalopathy was
defined as development of impairment of the conscious
state, the diagnosis of which was supported by blood
ammonia levels. Hyperbilirubinemia [100 lmol/l was
considered an indicator of liver failure. Hyperkalemia was
present when serum potassium level was [6.0 mmol/l,
requiring medical treatment for correction.
Statistical analysis
The Mann–Whitney U test was used to compare continuous
variables, and a chi-squared test was used to compare
discrete variables. Univariate analysis was used to identify
risk factors for patients developing serious complications.
Parameters included patient age, preprocedure levels of
serum bilirubin, albumin, alanine transaminase and aspar-
tate transaminase, platelet count, international normalized
ratio, total diameter of HCC, ablation time, ablation
energy, presence of cirrhosis on imaging, and comorbid
illness. Statistical significance was defined as p \ 0.05. All
statistical calculations were performed by using the SPSS/
PC ? computer software (SPSS, Chicago, IL).
Results
The 100 patients included in the study comprised 78 males
and 22 females, aged 34 to 85 (median, 65) years. Their
preoperative characteristics can be viewed in Table 1.
Premorbid medical diseases were present in 69 patients.
These diseases included hypertension (n = 27), ischemic
heart disease (n = 9), diabetes mellitus (n = 15), renal
impairment (n = 4), and other comorbidities (n = 20).
Twenty-seven patients received HIFU ablation as a pri-
mary treatment of HCC, and three patients received it as a
bridging therapy before liver transplantation. It also was
delivered as treatment of recurrence of HCC after TACE
(n = 41), partial hepatectomy (n = 28), and liver trans-
plantation (n = 1).
Fig. 1 After general anesthesia, patient on the platform was put in
the right lateral position. The transducer below the platform targeted
the liver lesion through the rib spaces
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Thirteen (13 %) patients developed a total of 18 com-
plications, either intraoperative or postoperative. Four
complications were grade 3a in the Clavien classification
and 14 were below this grade (Table 2). Univariate anal-
ysis was performed to evaluate the 20 factors that might
influence the patients’ tolerance of treatment (Table 3),
among which 1 factor was found to be significant and 19
factors were found to be insignificant. The only significant
factor was patient age (63 vs. 72 years, p = 0.022). The
complete ablation rate with single treatment was 87 % for
tumors \3 cm. No hospital mortality occurred during the
study period.
Discussion
Management of HCC remains a great challenge to clini-
cians despite new treatment modalities that keep emerging
and surgical techniques that keep improving. The challenge
is due to the fact that HCC is frequently accompanied by
cirrhosis. The combination of these two detrimental con-
ditions leads to an overall poor outcome in HCC patients.
Only 25 % of patients can be subjected to surgical inter-
vention upon diagnosis [18–20].
Many centers, including those with little experience in
resection of liver tumors for patients with cirrhosis, are
using RFA as a treatment modality due to its simplicity,
especially when compared with hepatectomy. However,
RFA is considered relatively contraindicated in patients
with advanced cirrhosis or gross ascites. In these patients,
the complication rate remains high.
For HIFU treatment, effective propagation of ultrasound
energy depends on a conductive medium with high density.
Thus, it can be performed safely in patients with gross
ascites, as shown in Fig. 2a, b. The ascites inside the per-
itoneal cavity not only provides a clear image for the
diagnostic ultrasound probe but also serves as a good
medium for energy transfer. The presence of ascites also
protects subcutaneous tissue from being damaged by the
focused ultrasound energy. So, poor liver function with
ascites is no longer a contraindication to HCC treatment.
In the present series, all HIFU ablations were performed
by a single team of experienced hepatic surgeons and
interventional radiologists to prevent bias that might
otherwise be brought about by operator variations. The
morbidity rate in the study was 13 %, which is comparable
to the morbidity rate after RFA in the same center. In fact,
many recent studies reported higher complication rates of
RFA, ranging from 13 to 20 % [21–23].
Although the ultrasound energy in HIFU treatment is
focused at the lesion, skin and subcutaneous tissue burns
did occur [8, 24]. Thermal injury can occur adjacent to the
target lesion or along the ultrasound beam pathway, par-
ticularly when treating subcapsular HCC that is located
closely to the subcutaneous area. Ultrasound possesses the
properties of sound waves, i.e., reflection, absorption,
refraction, and the cavitation effect of energy. These
unique features of ultrasound energy impart its diagnostic
Table 1 Preoperative characteristics of the 100 patients
No. of patients
(unless otherwise
stated)
Median age, year (range) 65 (34–85)
Male:female ratio 78:22
Median tumor size on CT scan, cm (range) 2.2 (0.9–8.0)
Median number of tumors to be treated
(range)
1 (1–2)
Hepatitis B virus carrier 80
Hepatitis C virus carrier 15
Presence of ascites 15
Cirrhotic liver on imaging 34
Child-Pugh grade A 84
Child-Pugh grade B 15
Child-Pugh grade C 1
ASA class 1 1
ASA class 2 65
ASA class 3 34
MELD score [ 14 5
ASA American Society of Anesthesiologists, MELD model of end-
stage liver disease
Table 2 Intraoperative and postoperative complications developed in
the 13 patients
Complication Number
Skin burn
First degree 5
Second degree 1
Third degree 3
Pleural effusion 1
Chest infection 1
Renal impairment 1
Variceal bleeding 1
Right chest wall bruising 1
Hyperbilirubinemia 1
Liver abscess 1
Pneumothorax 2
Total no. of complications 18
Clavien classification
3a 4
3b 0
4 0
5 0
Bold value indicates statistical significance (p \ 0.05)
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power by allowing visualization of the internal organ,
expression of the lesion by different ultrasound absorption
characteristics, and visualization of tumor destruction
during treatment. When the power of ultrasound is
increased in the treatment mode, some of the energy is
absorbed along the targeted lesion pathway. Most skin
burns occurred with tumors located near the subcapsular
area, where some of the energy was reflected by the ribs
overlying the tumor, and the abdominal wall was the first
tissue to absorb the energy.
There are two postulated mechanisms through which
HIFU damages the subcutaneous area: reflection from the
gas cavity and reflection by the ribs. Dubinsky et al. [25]
suggested that the reflection of ultrasound beam by the lung
parenchyma and bowel gas could cause burning of the
abdominal wall. The multiple layers of the abdominal wall
could be a good substance for absorption of energy present
in the gas-filled cavity inside the body. This is observed
more frequently in elderly patients, who are more likely to
have chronic obstructive airway diseases than younger
patients. A rib along the ultrasound beam also could absorb
excessive energy [26]. Although HIFU has an accurate
focusing property, the penetration of ultrasound wave is
largely hindered by the presence of ribs, particularly when
the tumor is close to the dome or the posterior section of
the liver, where the spaces between ribs are narrower. In
addition, bones have a high ultrasound absorption coeffi-
cient. This can cause overheating of the overlying
Table 3 Factors that might
influence the patients’ tolerance
of HIFU
Bold value indicates statistical
significance (p \ 0.05)
No complication
(n = 87)
With complication
(n = 13)
p value
Age (year) 63 (34–85) 72 (51–75) 0.022
Male:female ratio 68:19 10:3 1
ASA classification 0.804
1 1 (1.3 %) 0
2 52 (65.8 %) 13 (61.9 %)
3 26 (32.9 %) 8 (38.1 %)
Child-Pugh grade 0.927
A 73 11
B 13 2
C 1 0
Hepatitis B 70 10 1
Hepatitis C 12 3 0.647
Ascites 14 1 0.679
Cirrhotic liver on imaging 30/87 (34.48 %) 4/13 (30.76 %) 0.72
Alpha-fetoprotein (ng/ml) 18 (2–156600) 15 (2–1516) 0.538
Bilirubin (lmol/l) 14 (4–46) 14 (7–37) 0.762
Albumin (g/dl) 39 (24–50) 37 (27–42) 0.290
Aspartate transaminase (l/l) 47 (18–308) 40 (21–78) 0.198
Platelet count (9109/l) 99 (26–248) 121 (61–268) 0.23
International normalized ratio 1 (0.8–1.5) 1.1 (1–1.4) 0.601
Tumor size on CT scan (cm) 2.2 (0.9–8.0) 2.1 (1–5.7) 0.063
No. of tumors treated 1 (1–2) 1 (1–2) 0.295
Location of tumor 0.204
Section 2 1 (1.2 %) 2 (15.4 %)
Section 3 5 (6.0 %) 1 (7.7 %)
Section 4 5 (6.0 %) 0 (0 %)
Section 5 4 (4.8 %) 1 (7.7 %)
Section 6 10 (11.9 %) 2 (15.4 %)
Section 7 19 (22.6 %) 1 (2.8 %)
Section 8 22 (26.2 %) 3 (23.1 %)
Multiple ablations 21 (24.2 %) 3 (23.1 %)
Energy (J) 559906 (34477–19411678) 632641 (124414–1509327) 0.726
Average HIFU acoustic power (W) 370 (155–473) 380 (120–450) 0.806
HIFU exposure time (s) 1427 (135–7487) 1823 (338–5888) 0.575
2424 World J Surg (2012) 36:2420–2427
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subcutaneous tissue while effective energy may not be
transferred to the targeted area.
To overcome the problem of reflection of HIFU,
artificial pleural effusion is required for the ablation of
lesions adjacent to the ribs or close to the dome of the liver.
This is to displace the lung parenchyma from the pathway
of the ultrasound beam and to provide an acoustic window
for the treatment. Two patients in the present series
developed pneumothorax during introduction of hydro-
thorax. Although breathing is suspended, the introduction
of needle is a blind procedure and the depth of the pene-
tration varies from patient to patient as the subcutaneous
tissue’s thickness cannot be accurately predicted.
Theoretically, the introduction of hydrothorax can lead to
lung collapse and intrapulmonary shunting can occur.
Nonetheless, only one patient in the present series developed
intolerance and required drainage of pleural effusion.
Another patient, a chronic smoker, developed a chest
infection after the procedure, which fully resolved after
vigorous chest physiotherapy and antibiotics. In the majority
of patients, the artificial pleural effusion was rapidly absor-
bed after the procedure as shown by postoperative serial
chest X-ray investigations. Miserocchi [27] reported that
introduction of artificial pleural effusion actually increases
lymphatic drainage of the chest wall cavity.
Ventilation control can be a stressful challenge to
patients receiving HIFU treatment, especially for elderly
patients and patients with predisposing pulmonary disease.
To execute precise ablation as planned, immobilization is
required for lesions that move with respiration. Intermittent
breath holding at sustained airway pressure is necessary
during the procedure. A period of high positive inspired
pressure for up to 40 s can affect the cerebral blood flow,
which is already reduced in the elderly [28]. Fortunately,
no encephalopathy or cerebral vascular accident was noted
in the present series.
In the present study, patient age was the only significant
factor for treatment intolerance, as with other operations that
require general anesthesia. Aging is an inevitable physio-
logical phenomenon characterized by degenerative changes
in both the structure and the functional capacity of organs.
Elderly patients are prone to both dehydration and fluid
overload because of their weakened ability to concentrate
and dilute urine and to handle sodium. Chronic obstructive
pulmonary disease and pneumonia are very common among
the elderly. Closing volume increases with age, and forced
expiratory volume in 1 s declines 8–10 % per decade due to
reduced pulmonary compliance. As a result, risks of pneu-
mothorax, pneumonia, and pleural effusion increase when
the Valsalva maneuver is applied during general anesthesia.
Although the median size of tumors was 2 cm in the
present series, an 8-cm tumor in a patient with Child-Pugh
B cirrhosis was ablated with HIFU. This patient was denied
hepatectomy and RFA because of his poor liver function
and big tumor size. He tolerated the HIFU treatment well
and did not develop any complication. Unlike other ther-
mal ablative therapies, such as RFA and microwave abla-
tion, which produce heat that inevitably damages the
surrounding structure, HIFU produces very little collateral
damage beyond the targeted lesion. This is due to the
unique feature of its energy dissipation process. In HIFU
treatment, energy is transferred to the lesion at a very slow
pace. Each cycle of energy emission is separated by
1–2 min of resting, and each energy emission creates an
area of coagulative necrosis 1 cm only in diameter. The
surrounding liver parenchyma receives very little energy
and thus hardly gets any damage. This was evidenced by
the goods results of the present series as shown by post-
operative liver function tests and 1-month imaging scans.
No ablation of any unplanned area was found on the scans.
Very poor liver function, such as that possessed by
patients with Child-Pugh B or C cirrhosis, often gives rise
Fig. 2 a Computed tomography scan showing a hepatocellular
carcinoma at the dome of liver. The liver is of Child-Pugh C cirrhosis
with gross ascites. b Magnetic resonance imaging scan of the same
patient 1 month after high-intensity focused ultrasound (HIFU)
ablation. Complete ablation is noted in this scan. The patient’s liver
functions did not deteriorate from their pre-HIFU status
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to more complications after therapies, such as TACE, RFA,
and hepatectomy. It seems, however, that HIFU can deal
with very poor liver function successfully. Among 100
patients, there were 84 Child-Pugh A, 15 Child-Pugh B,
and 1 Child-Pugh C, yet no association between intolerance
of treatment and liver function was found. It is believed
that HIFU is safe for patients with gross ascites, which is a
sign of decompensated cirrhosis.
Conclusions
This study is the first to examine HCC patients’ tolerance of
HIFU and to analyze factors that affect such tolerance.
Patient age is the only factor that was found to be significant
in HIFU intolerance. HIFU ablation is a generally well-tol-
erated treatment modality. It is safe for Child-Pugh A and B
patients and selected Child-Pugh C patients. With this new
modality, HCC patients who were deemed unsalvageable by
other surgical means in the past because of simultaneous
Child-Pugh B or C disease now have a new hope.
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